The latest price target for Vincerx Pharma (NASDAQ:VINC) was reported by Leerink Partners on October 8, 2024. The analyst firm set a price target for $2.00 expecting VINC to rise to within 12 months (a possible 690.20% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Vincerx Pharma (NASDAQ:VINC) was provided by Leerink Partners, and Vincerx Pharma maintained their outperform rating.

There is no last upgrade for Vincerx Pharma

There is no last downgrade for Vincerx Pharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vincerx Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vincerx Pharma was filed on October 8, 2024 so you should expect the next rating to be made available sometime around October 8, 2025.

While ratings are subjective and will change, the latest Vincerx Pharma (VINC) rating was a maintained with a price target of $4.00 to $2.00. The current price Vincerx Pharma (VINC) is trading at is $0.25, which is out of the analyst’s predicted range.